The glycemic management of people with type 1 diabetes and type 2 diabetes and the respective kidney benefits require separate considerations, which in part reflects the different evidence base and lifetime risks of complications with the greater risk for hypoglycemia that arises when several concurrent therapies are used alongside insulin as kidney function deteriorates.1 Here, INS is linked to Hypoglycemia.